Alkermes PLC (ALKS): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Alkermes ( ALKS) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 1.8%. By the end of trading, Alkermes fell $0.55 (-1.6%) to $33.07 on average volume. Throughout the day, 1,095,240 shares of Alkermes exchanged hands as compared to its average daily volume of 939,800 shares. The stock ranged in price between $32.29-$33.41 after having opened the day at $32.92 as compared to the previous trading day's close of $33.62. Other companies within the Drugs industry that declined today were: Mast Therapeutics ( MSTX), down 40.3%, Achillion Pharmaceuticals ( ACHN), down 12.2%, CEL-SCI Corporation ( CVM), down 11.8% and Prana Biotechnology ( PRAN), down 8.3%.

Alkermes Public Limited Company, an integrated biopharmaceutical company, develops medicines that enhance patient outcomes. Alkermes has a market cap of $4.6 billion and is part of the health care sector. Shares are up 81.8% year to date as of the close of trading on Monday. Currently there are 7 analysts that rate Alkermes a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates Alkermes as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we find that the growth in the company's net income has been quite unimpressive.

On the positive front, GW Pharmaceuticals PLC ADR ( GWPH), up 89.4%, pSivida ( PSDV), up 30.9%, Lexicon Pharmaceuticals ( LXRX), up 21.4% and Mirati Therapeutics ( MRTX), up 16.6% , were all gainers within the drugs industry with Merck ( MRK) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

The 6 Medications Being Used to Tackle the Opioid Epidemic

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Verizon, Randgold Resources, Bank of America: 'Mad Money' Lightning Round